Pipelines
The company continues to be oriented towards innovation and internationalization, increasing investments in research and development and the recruitment of scientific research personnesl. Through independent research and development, cooperative development, licensing, deep incubation, and other diversification a multi-level cooperation model,that enriches the pipeline of innovative products, enhances the research and development and clinical capabilities of new drugs, and accelerates the development and transformation of innovative technologies and products has been set up.
| Drug | Target of action | Indication | Dosage form | Target validation | Lead optimization | Preclinical study | IND | Phase I | Phase II | Phase III | Pre-NDA | NDA |
|
Peceleganan (PL-5) |
Bacterial cell membrane | Secondary wound infection (China) | Spray |
|
||||||||
| Diabetic foot infection (USA) | Spray |
|
||||||||||
| PL-18 | Bacterial/fungal cell membrane | Colpomycosis, Bacterial Vaginosis, Mixed Vaginitis （USA） | Suppository |
|
||||||||
| Colpomycosis（China） | Suppository |
|
||||||||||
| PL-3301 | Bacterial/fungal cell membrane | Oropharyngeal Candidiasis | Oral gel |
|
||||||||
| Acute bacterial skin and skin structure infections（ABSSSI） | Hydrogel nanoneedle |
|
||||||||||
| Pulmonary infection | Inhalant |
|
||||||||||
| PL-4902 | Bacterial cell membrane | Systemic/pulmonary infection | Injection |
|
||||||||
| PL-AC-333（DNW-002） | Undisclosed | Inflammatory bowel disease (IBD) | Oral (Small molecule) |
|
||||||||
| Obesity | ||||||||||||
| PL -AC2001 | Undisclosed | Three negative breast cancer, colorectal cancer | Oral (PROTAC) |
|
||||||||
